![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Bushnell Cheryl
Publisher: Informa Healthcare
ISSN: 1474-0338
Source: Expert Opinion on Drug Safety, Vol.4, Iss.3, 2005-05, pp. : 501-507
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Tamoxifen use associated with reduction in breast density
Inpharma, Vol. 1, Iss. 1436, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Risks associated with the therapeutic use of fluoroquinolones
By Stahlmann Ralf Lode Hartmut M
Expert Opinion on Drug Safety, Vol. 12, Iss. 4, 2013-07 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Tamoxifen associated with uterine sarcoma
Inpharma, Vol. 1, Iss. 1342, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Potential Risks Associated with the Use of Herbal Anti-Obesity Products
Drug Safety, Vol. 32, Iss. 6, 2009-05 ,pp. :